ex_img03.jpg

Translational Medicine

Furthering progress in Translational Medicine – moving from bench to bedside to turn breakthrough research discoveries into healthcare solutions – InnaVirVax is proud to collaborate with leading academic institutions.

Home_Investor.jpg

Invest for the future

InnaVirVax continuously expands its network with the primary objectives of accessing external resources, incorporating expertise and knowledge so as to optimize time to market and continuously improving its pipeline.

ex_img01.jpg

Patient

Patients are at the core of our research to improve their quality of life.

InnaVirVax

About us

InnaVirVax is a privately-owned clinical stage biotechnology company developing cutting-edge, immune-based treatments for infectious and major chronic diseases. These therapies are based on a versatile platform to enable the development of targeted vaccines.

Events
2013
December
01
InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used in Combination With Standard Antiretroviral Therapy in Treatment of HIV-Infection.
October
07
InnaVirVax presented two posters at Barcelona, AIDS Vaccine 2103 Conference.
September
01
An article entitled  "A Single Amino-acid Change in a Highly Conserved Motif of gp41 Elicits Virus Neutralization and Protects against CD4 Depletion" was published in Clinical Infectious Diseases.
July
16
An article entitled "NKp44L expression on CD4+ T cells is associated with impaired immunological recovery in HIV-infected patients under highly active antiretroviral therapy" was published online in AIDS.
July
01
An article published in Biotech Finances, the leading European weekly newsletter dedicated to all the financial aspects of biotechnology, reports that InnaVirVax is efficiently pursuing the clinical development of VAC-3S.
June
12
InnaVirVax presented a poster at the 14th Journées Nationales d’Infectiologie, Clermont-Ferrand, France
May
23
InnaVirVax presented a poster at the international symposium "30 years of HIV science : Imagine the future" held at Institut Pasteur.
May
10
The BioPharmaAnalyses newsletter marks InnaVirVax's fifth birthday!
March
05
InnaVirVax presented during the 20th Conference on Retroviruses and Opportunistic Infections in Atlanta the interim findings from its Phase I/IIa study confirming the safety of VAC-3S and demonstrating its immunogenicity.
January
24
InnaVirVax participated in the workshop entitled "HIV cure and eradication: a feasible option?" in Milan, Italy.